News

We are pleased to announce that we have hired Jesper Kjerulff, starting on June 1st, to serve as the project leader for the continued development of our candidate compound PN6047 and lead the project into phase 1 clinical trials in Q2 2022.

Hans G. Nilsson, PhD (1943–2021), has during a cross country ski trip on a beautiful Sunday in January 2021, unexpectedly left us in grief and mourning.

We are pleased to announce that PharmNovo AB has been granted a patent for our candidate PN6047 in China. PharmNovo AB is currently entering into regulatory toxicology studies with PN6047 – an exciting phase in the development of this biased delta opioid receptor agonist (DOBRA) favouring signalling through G proteins. In preclinical testing, our candidate effectively reduces neuropathic pain without any of the unwanted side effects of conventional opioids.

PharmNovo is pleased to announce that Helen Pettersson is now a member of the board, representing Almi Invest and Almi Invest Syd, being one of the larger investors in PharmNovo AB.

PharmNovo has completed a new share issue of 22 million SEK with the Sciety investment syndicate as the lead investor.

As a result of our publication in JPET with University of Bristol, contact was established with Prof. Amynah Pradhan at the University of Illinois, Chicago.